An Overview of Biomarkers for the Diagnosis of Hepatocellular Carcinoma

Context Primary liver cancer is one of the most common and deadly malignant neoplasms worldwide. The incidence and mortality rates for hepatocellular carcinoma (HCC) are virtually identical, reflecting the poor overall survival of patients with this kind of tumor. Effective therapies mostly achieved if the HCC diagnosis is made at early stages of the tumor. Surveillance tests include serologic and radiologic examinations. Evidence Acquisition In this review, an overview of biomarkers for the diagnosis of HCC and future challenges in this popular field has been presented. Results Serum tumor markers, such as alpha-fetoprotein (AFP) and des-gammacarboxy prothrombin (DCP) are commonly used for the surveillance, but their roles have been intensely debated despite the existence of sensitive radiologic tests. Most HCC-related cancer biomarkers are involved in chronic inflammation and cancer. These biomarkers, according to their biologic characteristics are primarily divided into three groups including onco-foetal protein, stress protein, and post-translational modification. Conclusions Because of the limitations of traditional HCC biomarkers, exploration for novel biomarkers for the diagnosis of HCC is an evolving process.

• Publication year

  2012

• Venue

  Hepatitis Monthly

• Publication date

  2012-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.5812/hepatmon.6122PMID 23162601PMCID 3496856
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Diagnostic significance of plasma osteopontin in hepatitis C virus-related hepatocellular carcinoma.

  2011cited by this paper
• Management of hepatocellular carcinoma: An update

  2011cited by this paper
• Gene Signatures Derived from a c-MET-Driven Liver Cancer Mouse Model Predict Survival of Patients with Hepatocellular Carcinoma

  2011cited by this paper
• Diagnostic and prognostic value of alpha-fetoprotein, des-γ-carboxy prothrombin and squamous cell carcinoma antigen immunoglobulin M complexes in hepatocellular carcinoma.

  2011cited by this paper
• The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma.

  2010cited by this paper
• Osteopontin: an effector and an effect of tumor metastasis.

  2010cited by this paper
• Seroprevalence of hepatitis C and B among blood donors in Egypt: Minya Governorate, 2000-2008.

  2010cited by this paper
• Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.

  2009cited by this paper
• Epidemiology of hepatitis viruses among hepatocellular carcinoma cases and healthy people in Egypt: A systematic review and meta‐analysis

  2009cited by this paper
• Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma.

  2009cited by this paper
• Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma.

  2009cited by this paper
• Using proteomic approach to identify tumor-associated antigens as markers in hepatocellular carcinoma.

  2008cited by this paper
• Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis.

  2008cited by this paper
• Evaluation of serum squamous cell carcinoma antigen as a novel biomarker for diagnosis of hepatocellular carcinoma in Egyptian patients.

  2008cited by this paper
• Evidence-based clinical practice guidelines for hepatocellular carcinoma in Japan: the J-HCC guidelines

  2008cited by this paper
• Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications.

  2008cited by this paper
• The role of glypican-3 in the regulation of body size and cancer

  2008cited by this paper
• Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States.

  2007cited by this paper
• Clinical Utility of AFP-L3% Measurement in North American Patients with HCV-Related Cirrhosis

  2007cited by this paper
• Prognostic molecular markers in hepatocellular carcinoma: a systematic review.

  2007cited by this paper
• Hepatocellular carcinoma: epidemiology and molecular carcinogenesis.

  2007cited by this paper
• Des-gamma-carboxyl prothrombin-promoted vascular endothelial cell proliferation and migration.

  2007cited by this paper
• Prognostic factors for portal venous invasion in patients with hepatocellular carcinoma

  2007cited by this paper
• Non-alcoholic steatohepatitis and cancer.

  2007cited by this paper
• Cancer incidence in four member countries (Cyprus, Egypt, Israel, and Jordan) of the Middle East Cancer Consortium (MECC) compared with US SEER.

  2006cited by this paper
• Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma.

  2006cited by this paper
• A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis.

  2006cited by this paper
• Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues

  2006cited by this paper
• Downregulation of miR‐122 in the rodent and human hepatocellular carcinomas

  2006cited by this paper
• New frontiers in biomarkers for hepatocellular carcinoma.

  2006cited by this paper
• Assessment of KL-6 as a tumor marker in patients with hepatocellular carcinoma.

  2005cited by this paper
• GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma.

  2005influential reference
• Des-gamma-carboxy prothrombin is a potential autologous growth factor for hepatocellular carcinoma.

  2005cited by this paper
• Detection of serum and intrahepatic KL-6 in anti-HCV positive patients with hepatocellular carcinoma.

  2004cited by this paper
• Evaluation of serum KL-6 as a predictive marker of radiation pneumonitis in patients with breast-conservation therapy

  2004cited by this paper
• Disease- and Cell-Specific Expression of GP73 in Human Liver Disease

  2004cited by this paper
• Primary liver cancer: worldwide incidence and trends.

  2004cited by this paper
• Tissue and Serum MUC1 Mucin Detection in Breast Cancer Patients

  2003cited by this paper
• Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma.

  2003cited by this paper
• Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma

  2003cited by this paper
• Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma.

  2003cited by this paper
• Expression profiling in multistage hepatocarcinogenesis: Identification of HSP70 as a molecular marker of early hepatocellular carcinoma

  2003cited by this paper
• Glypican‐3 is overexpressed in human hepatocellular carcinoma

  2003cited by this paper
• Des‐gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients

  2003cited by this paper
• Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker.

  2003cited by this paper
• Screening for hepatocellular carcinoma.

  2002cited by this paper
• Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease

  2002cited by this paper
• Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum des-gamma-carboxy prothrombin: a prospective study.

  2002cited by this paper
• AFP-L3: a new generation of tumor marker for hepatocellular carcinoma.

  2001cited by this paper
• Comparison of clinicopathological features of patients with hepatocellular carcinoma seropositive for α‐fetoprotein alone and those seropositive for des‐γ‐carboxy prothrombin alone 1

  2001cited by this paper
• Alpha-fetoprotein Structure and Function: Relevance to Isoforms, Epitopes, and Conformational Variants

  2001cited by this paper
• Glypicans: proteoglycans with a surprise.

  2001cited by this paper
• Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation

  2000cited by this paper
• Screening for hepatocellular carcinoma

  1998cited by this paper
• Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Comparison with alpha‐fetoprotein

  1994cited by this paper
• Sugar chains of human cord serum alpha-fetoprotein: characteristics of N-linked sugar chains of glycoproteins produced in human liver and hepatocellular carcinomas.

  1993cited by this paper
• Regulation of human lymphocyte activation by alpha-fetoprotein. Evidence for selective suppression of Ia-associated T-cell proliferation in vitro.

  1982cited by this paper
• Production of embryonal serum alpha-globulin by hepatomas: review of experimental and clinical data.

  1968cited by this paper
• Demonstration of a new protein fraction in serum from the human fetus.

  1956cited by this paper

• Physiopathological Features in a Three-Dimensional In Vitro Model of Hepatocellular Carcinoma: Hypoxia-Driven Oxidative Stress and ECM Remodeling

  2025cites this paper
• An Unusual Presentation of Hepatocellular Carcinoma: A Case Report

  2024cites this paper
• A Preclinical Study on 4-Methyl-N-((4-(trifluoromethoxy)phenyl) carbamoyl)-benzenesulfonamide as a Potent Chemotherapeutic Agent against Liver and Pancreatic Carcinogenesis in Rats: Immunohistochemical and Histopathological Studies.

  2024cites this paper
• Causal discoveries for high dimensional mixed data

  2022cites this paper
• Research Progress in Alpha-Fetoprotein-Induced Immunosuppression of Liver Cancer.

  2022cites this paper
• Diagnostic Accuracy of Plasma Osteopontin in Egyptian Hepatocellular ‎Carcinoma Patients

  2022cites this paper
• Value of Hypermethylation (RASSF1A) Promoter Gene among Value of Hypermethylation (RASSF1A) Promoter Gene among Patients with Hepatocellular Carcinoma Patients with Hepatocellular Carcinoma

  2020cites this paper
• Influence of Alanine Transaminase Levels on Alpha-Fetoprotein for Predicting Hepatocellular Carcinoma in Patients with Hepatitis B Infection

  2020cites this paper
• Evaluation of plasma D-dimer for the diagnosis in Chinese patients with hepatocellular carcinoma

  2020cites this paper
• Role Of Serum Glypican 3 As A Predictive Tool For Early Diagnosis Of Hepatocellular Carcinoma (HCC)

  2020cites this paper
• Clinical Implications of Alanine Transaminase Level in the Diagnostic Accuracy of Alpha-Fetoprotein for Predicting Hepatocellular Carcinoma in Patients with Hepatis B Infection

  2020cites this paper
• Pleomorphic adenoma gene 1 expression is associated with the diagnosis of hepatocellular carcinoma

  2020cites this paper
• Clinical Implications of Alanine Transaminase Level in the Diagnostic Accuracy of Alpha-Fetoprotein for Predicting Hepatocellular Carcinoma in Patients with Hepatis B Infection

  2020cites this paper
• Serum Serotonin as a Potential Diagnostic Marker for Hepatocellular Carcinoma

  2019cites this paper
• More Than a Tumor Marker…A Potential Role for Alpha-Feto Protein in Inflammatory Bowel Disease.

  2019cites this paper
• Diagnostic Value of Glypican-3 for Hepatocellular Carcinomas

  2018cites this paper
• Potential use of TIA-1, MFF, microRNA-200a-3p, and microRNA-27 as a novel marker for hepatocellular carcinoma.

  2018cites this paper
• Study of P53 Gene Mutations as a New Early Diagnostic Markers of Hepatocellular Carcinoma in Egyptian Patients

  2018cites this paper
• Modeling Liver Diseases Using Hepatic Cell Microarrays

  2018cites this paper
• Genes directly regulated by NF-κB in human hepatocellular carcinoma HepG2.

  2017cites this paper
• Variety and Dynamics of Proteoforms in the Human Proteome: Aspects of Markers for Hepatocellular Carcinoma

  2017cites this paper
• Des-γ carboxyprothrombin may not be a good biomarker for hepatocellular carcinoma in those chronically infected with hepatitis B virus with basal core promoter double mutations (T^{1762}, A^{1764}), a prospective study

  2017cites this paper
• Knowledge and practice on magnitude, diagnosis, treatment and prevention strategies of Hepatocellular Carcinoma in Ethiopia: A Systematic Review

  2017cites this paper
• Glypican-3 versus alpha-fetoprotein as a biomarker for hepatocellular carcinoma: a diagnostic meta-analysis

  2016cites this paper
• Serum protein biomarkers relevant to hepatocellular carcinoma and their detection.

  2016cites this paper
• Hepatocellular carcinoma: Review of disease and tumor biomarkers.

  2016cites this paper
• Circulating microRNA-200 Family as Diagnostic Marker in Hepatocellular Carcinoma

  2015cites this paper
• Evaluation of the diagnostic value of alpha-l-fucosidase, alpha-fetoprotein and thymidine kinase 1 with ROC and logistic regression for hepatocellular carcinoma

  2015cites this paper
• Circulating biomarkers of hepatocellular carcinoma response after locoregional treatments: New insights.

  2015cites this paper
• Protein microarray with horseradish peroxidase chemiluminescence for quantification of serum α-fetoprotein

  2015cites this paper
• Adult hepatic cavernous hemangioma with highly elevated α-fetoprotein: A case report and review of the literature

  2014cites this paper
• The microRNA‐200 family—A potential diagnostic marker in hepatocellular carcinoma?

  2014cites this paper
• Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins

  2014cites this paper
• Primary liver cancer: Epidemiological and Biomarker Discovery Studies

  2014cites this paper
• Personalized Medicine and Imaging Serum Interleukin-8 Re fl ects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins

  2014cites this paper
• Identification of AKT kinases as unfavorable prognostic factors for hepatocellular carcinoma by a combination of expression profile, interaction network analysis and clinical validation.

  2014cites this paper
• Can Serum Glypican-3 Be a Biomarker for Effective Diagnosis of Hepatocellular Carcinoma? A Meta-Analysis of the Literature

  2014cites this paper
• Association of Mammographic Density with Pathologic Findings

  2013cites this paper
• Different Faces of Hepatocellular Carcinoma as a Health Threat in 21st Century

  2013cites this paper
• Type 1 insulin-like growth factor receptor monoclonal antibody (HX-1162) treatment for liver cancer

  2013cites this paper
• Decreased expression of SOX6 confers a poor prognosis in hepatocellular carcinoma.

  2013cites this paper
• Role Of Serum Glypican 3 As A Predictive Tool For Early Diagnosis Role Of Serum Glypican 3 As A Predictive Tool For Early Diagnosis Of Hepatocellular Carcinoma (HCC) Of Hepatocellular Carcinoma (HCC)

  year unknowncites this paper